Crossject Logo

Crossject

Develops emergency medications delivered via a needle-free auto-injector platform.

ALCJ | PA

Overview

Corporate Details

ISIN(s):
FR0004178614 (+6 more)
LEI:
969500W1VTFNL2D85A65
Country:
France
Address:
6 Rue Pauline Kergomard, 21000 dijon

Description

Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-02-07 18:04
CROSSJECT : Nombre total de droits de vote et d'actions
French 71.1 KB
2019-01-29 19:16
CROSSJECt : OBTENTION DU STATUT D ETABLISSEMENT PHARMACEUTIQUE
French 69.6 KB
2019-01-16 18:38
CROSSJECT : nb total de droits de vote et d'actions
French 361.7 KB
2019-01-16 18:28
CROSSJECT : Bilan semestriel de liquidité de Crossject au 31/12/2018
French 323.1 KB
2018-12-21 07:00
CROSSJECT : Succes de l'augmentation de capital d'un montant de 4M€
French 633.5 KB
2018-12-11 18:07
CROSSJECT : nb total de droits de vote et d'actions
French 362.5 KB
2018-11-27 18:47
CROSSJECT : Augmentation de capital avec maintien du DPS
French 1.8 MB
2018-11-21 18:58
CROSSJECT : point d'activité - novembre 2018
French 644.4 KB
2018-11-15 18:42
CROSSJECT : nb total de droits de vote et d'actions
French 370.8 KB
2018-06-18 18:27
CROSSJECT : nb total de droits de vote et d'actions
French 446.6 KB
2018-06-18 18:19
Cossject : Descriptif du programme de rachat d'actions 2018-2019
French 629.2 KB
2018-06-18 18:10
CROSSJECT: Résultats des votes de l'AG du 17 mai 2018
French 436.2 KB
2018-05-23 18:08
CROSSJECT éligible au PEA-PME
French 393.5 KB
2018-05-16 18:28
CROSSJECT : Point d'activité mai 2018
French 575.2 KB
2018-05-11 20:03
CROSSJECT : Information relative au nb total de ddv et d'actions
French 476.5 KB

Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Crossject

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Crossject via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-24 N/A Other Buy 20,000 N/A
2024-06-14 N/A Other Other 10,979 20,289.19 EUR
2024-06-06 N/A Other Other 1,058,617 1,956,324.22 EUR
2024-06-06 N/A Other Other 16,106 29,763.89 EUR
2024-06-06 N/A Other Other 10,275 18,988.20 EUR
2024-06-06 N/A Other Other 10,074 18,616.75 EUR
2024-06-06 N/A Other Buy 5,536 10,230.53 EUR
2023-03-06 N/A Other Other 22,859 75,434.70 EUR

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.